PT  - JOURNAL ARTICLE
AU  - Sait, Hesham K.
AU  - Anfinan, Nisreen M.
AU  - El Sayed, Mohamed E.
AU  - Alkhayyat, Shadi S.
AU  - Ghanem, Ahmed T.
AU  - Abayazid, Reem M.
AU  - Sait, Khalid H.
TI  - Uterine sarcoma. Clinico-pathological characteristics and outcome
DP  - 2014 Oct 01
TA  - Saudi Medical Journal
PG  - 1215--1222
VI  - 35
IP  - 10
4099  - http://smj.org.sa/content/35/10/1215.short
4100  - http://smj.org.sa/content/35/10/1215.full
SO  - Saudi Med J2014 Oct 01; 35
AB  - OBJECTIVES: To investigate the clinical and histopathological characteristics, with the prognostic factors, treatment outcome, pattern of relapse, and survival analysis of uterine sarcoma patients.METHODS: All patients with histologically proven uterine sarcoma were identified using the database at King Abdulaziz University Hospital, Jeddah, Saudi Arabia between January 2000 and December 2012.RESULTS: A total of 36 patients with uterine sarcoma were reviewed. The median age of all patients was 57 years, and the mean age was 57.72+/-13.17 years. Carcinosarcoma was reported in 21 patients (58%), leiomyosarcoma in 7 (19%), undifferentiated endometrial sarcoma in 6 (17%), and rhabdomyosarcoma in 2 (6%). Approximately half of the patients were stages III and IV (28% and 25%), while 15 patients (41%) were stage I; only 2 patients (6%) were stage II. The surgical treatment was hysterectomy and bilateral salpingoophorectomy (H+BSO) plus staging in 18 patients (50%), while in 4 patients (19%), H+BSO plus debulking was performed. Adjuvant chemotherapy was given in 24 (69%) and adjuvant radiotherapy in 5 (14%) cases, At a median follow-up period of 13.5 months, 8 patients (22%) relapsed. The 2-year disease-free survival (DFS) rate was 22% and the 5-year was 14%. In the multivariate analysis, the advanced stages (p=0.015) and lymph vascular invasion (p=0.0001) were associated with poor DFS, while the use of chemotherapy significantly improved the DFS (p=0.027). Conclusions: The poor outcome of high-grade uterine sarcoma patients was identified, and only one third of patients (30%) survived for 2 years. This finding necessitates the need for more aggressive tools to fight this disease.